Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double-blind Controlled Exploratory Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients

NCT05923905 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT05923905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05923905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double-blind Controlled Exploratory Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
Lead sponsor
Peking University Third Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
January 18, 2023
Completion date
September 30, 2027
Enrollment
64 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sporadic and familial amyotrophic lateral sclerosis